GNE-617
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407304

CAS#: 1362154-70-8

Description: GNE-617 is a potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with IC50 value of 5nM. Prolonged inhibition of nicotinamide phosphoribosyltransferase (NAMPT) is a strategy for targeting cancer metabolism.


Chemical Structure

img
GNE-617
CAS# 1362154-70-8

Theoretical Analysis

MedKoo Cat#: 407304
Name: GNE-617
CAS#: 1362154-70-8
Chemical Formula: C21H15F2N3O3S
Exact Mass: 427.08
Molecular Weight: 427.426
Elemental Analysis: C, 59.01; H, 3.54; F, 8.89; N, 9.83; O, 11.23; S, 7.50

Price and Availability

Size Price Availability Quantity
25mg USD 250
50mg USD 450
100mg USD 750
200mg USD 1250
500mg USD 2250 2 Weeks
1g USD 3250
2g USD 5850 2 Weeks
Bulk inquiry

Synonym: GNE-617; GNE 617; GNE617.

IUPAC/Chemical Name: N-(4-((3,5-difluorophenyl)sulfonyl)benzyl)imidazo[1,2-a]pyridine-6-carboxamide

InChi Key: XRDVXQQZLHVEQZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H15F2N3O3S/c22-16-9-17(23)11-19(10-16)30(28,29)18-4-1-14(2-5-18)12-25-21(27)15-3-6-20-24-7-8-26(20)13-15/h1-11,13H,12H2,(H,25,27)

SMILES Code: O=C(C1=CN2C(C=C1)=NC=C2)NCC3=CC=C(S(=O)(C4=CC(F)=CC(F)=C4)=O)C=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: GNE-617 is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC50 of 5 nM.
In vitro activity: To test whether pharmacological NAMPT inhibition resulted in similar cytotoxicity in IDH1R132H cells to the esiRNA-mediated NAMPT knockdown, this study exposed cells to the chemically distinct, specific NAMPT inhibitors FK866, GMX1778 and GNE-617. Each inhibitor reduced the metabolic activity—quantified via the NAD(P)H-dependent WST-1-reduction rate—after 48 h of treatment in a concentration-dependent manner (Figure 5A). The IC50 values were determined to be 36.8 nM, 19.9 nM and 27.9 nM for FK866, GMX1778 and GNE-617, respectively. Reference: Int J Mol Sci. 2022 May 21;23(10):5787. https://pubmed.ncbi.nlm.nih.gov/35628596/
In vivo activity: GNE-617 was highly efficacious and induced tumor regression within 5 days of twice daily treatment at MTDs of 10 to 15 mg/kg (20 to 30 mg/kg total dose/day) in the HCT-116 [%TGI at 15 mg/kg, twice daily = 87 (95% CI = 78, 94)], MiaPaCa-2 [%TGI at 10 mg/kg, twice daily = 91 (95% CI = 87, 95)], PC3 [%TGI at 15 mg/kg, twice daily = 168 (95% CI = 122, 476)], and HT-1080 [%TGI at 15 mg/kg, twice daily = 143 (95% CI = 107, 438)] xenograft models (Figures 1, A–D, and W2). Reference: Neoplasia. 2013 Dec;15(12):1314-29. https://pubmed.ncbi.nlm.nih.gov/24403854/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMF 20.0 46.79
DMSO 78.7 26.22
DMSO:PBS (pH 7.2) (1:4) 0.2 0.47

Preparing Stock Solutions

The following data is based on the product molecular weight 427.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Clausing M, William D, Preussler M, Biedermann J, Grützmann K, Richter S, Buchholz F, Temme A, Schröck E, Klink B. Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model. Int J Mol Sci. 2022 May 21;23(10):5787. doi: 10.3390/ijms23105787. PMID: 35628596; PMCID: PMC9143996. 2. Ogino Y, Sato A, Uchiumi F, Tanuma SI. Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment. Oncotarget. 2018 Mar 27;9(23):16451-16461. doi: 10.18632/oncotarget.24731. PMID: 29662658; PMCID: PMC5893253. 3. O'Brien T, Oeh J, Xiao Y, Liang X, Vanderbilt A, Qin A, Yang L, Lee LB, Ly J, Cosino E, LaCap JA, Ogasawara A, Williams S, Nannini M, Liederer BM, Jackson P, Dragovich PS, Sampath D. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models. Neoplasia. 2013 Dec;15(12):1314-29. doi: 10.1593/neo.131718. PMID: 24403854; PMCID: PMC3884523.
In vitro protocol: 1. Clausing M, William D, Preussler M, Biedermann J, Grützmann K, Richter S, Buchholz F, Temme A, Schröck E, Klink B. Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model. Int J Mol Sci. 2022 May 21;23(10):5787. doi: 10.3390/ijms23105787. PMID: 35628596; PMCID: PMC9143996. 2. Ogino Y, Sato A, Uchiumi F, Tanuma SI. Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment. Oncotarget. 2018 Mar 27;9(23):16451-16461. doi: 10.18632/oncotarget.24731. PMID: 29662658; PMCID: PMC5893253.
In vivo protocol: 1. O'Brien T, Oeh J, Xiao Y, Liang X, Vanderbilt A, Qin A, Yang L, Lee LB, Ly J, Cosino E, LaCap JA, Ogasawara A, Williams S, Nannini M, Liederer BM, Jackson P, Dragovich PS, Sampath D. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models. Neoplasia. 2013 Dec;15(12):1314-29. doi: 10.1593/neo.131718. PMID: 24403854; PMCID: PMC3884523.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Preyat N, Leo O. Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways. Biochem Pharmacol. 2016 Feb 1;101:13-26. doi: 10.1016/j.bcp.2015.08.110. Epub 2015 Sep 3. PubMed PMID: 26343585.

2: Zak M, Liederer BM, Sampath D, Yuen PW, Bair KW, Baumeister T, Buckmelter AJ, Clodfelter KH, Cheng E, Crocker L, Fu B, Han B, Li G, Ho YC, Lin J, Liu X, Ly J, O'Brien T, Reynolds DJ, Skelton N, Smith CC, Tay S, Wang W, Wang Z, Xiao Y, Zhang L, Zhao G, Zheng X, Dragovich PS. Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility. Bioorg Med Chem Lett. 2015 Feb 1;25(3):529-41. doi: 10.1016/j.bmcl.2014.12.026. Epub 2014 Dec 17. PubMed PMID: 25556090.

3: Zabka TS, Singh J, Dhawan P, Liederer BM, Oeh J, Kauss MA, Xiao Y, Zak M, Lin T, McCray B, La N, Nguyen T, Beyer J, Farman C, Uppal H, Dragovich PS, O'Brien T, Sampath D, Misner DL. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. Toxicol Sci. 2015 Mar;144(1):163-72. doi: 10.1093/toxsci/kfu268. Epub 2014 Dec 11. PubMed PMID: 25505128.

4: Del Nagro C, Xiao Y, Rangell L, Reichelt M, O'Brien T. Depletion of the central metabolite NAD leads to oncosis-mediated cell death. J Biol Chem. 2014 Dec 19;289(51):35182-92. doi: 10.1074/jbc.M114.580159. Epub 2014 Oct 29. PubMed PMID: 25355314; PubMed Central PMCID: PMC4271207.

5: Liang X, Yang L, Qin AR, Ly J, Liederer BM, Messick K, Ma S, Zak M, Dragovich PS, Dean BJ, Hop CE, Deng Y. Measuring NAD(+) levels in mouse blood and tissue samples via a surrogate matrix approach using LC-MS/MS. Bioanalysis. 2014 Jun;6(11):1445-57. doi: 10.4155/bio.14.8. Erratum in: Bioanalysis. 2014;6(13):1870. PubMed PMID: 25046046.

6: Oh A, Ho YC, Zak M, Liu Y, Chen X, Yuen PW, Zheng X, Liu Y, Dragovich PS, Wang W. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase. Chembiochem. 2014 May 26;15(8):1121-30. doi: 10.1002/cbic.201402023. Epub 2014 May 5. PubMed PMID: 24797455.

7: O'Brien T, Oeh J, Xiao Y, Liang X, Vanderbilt A, Qin A, Yang L, Lee LB, Ly J, Cosino E, LaCap JA, Ogasawara A, Williams S, Nannini M, Liederer BM, Jackson P, Dragovich PS, Sampath D. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models. Neoplasia. 2013 Dec;15(12):1314-29. PubMed PMID: 24403854; PubMed Central PMCID: PMC3884523.

8: Shames DS, Elkins K, Walter K, Holcomb T, Du P, Mohl D, Xiao Y, Pham T, Haverty PM, Liederer B, Liang X, Yauch RL, O'Brien T, Bourgon R, Koeppen H, Belmont LD. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors. Clin Cancer Res. 2013 Dec 15;19(24):6912-23. doi: 10.1158/1078-0432.CCR-13-1186. Epub 2013 Oct 4. PubMed PMID: 24097869.